Drugs for Steatorrhea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 33)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Pancrelipase |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
53608-75-6 |
|
Synonyms:
lipase
Pancrealipase
Pancreatic extract pancrelipase
Pancreatic protease
|
Pancreatin
Pancreatinum
Pancrelipase (amylase
protease)
|
|
2 |
|
Gastrointestinal Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
3 |
|
pancreatin |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
4 |
|
Omeprazole |
Approved, Investigational, Vet_approved |
Phase 3 |
|
73590-58-6 |
4594
|
Synonyms:
( -)-Omeprazole
(-)-Omeprazole
(S)-(-)-Omeprazole
(S)-Omeprazole
119141-89-8
131959-78-9
172964-80-6
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
2,3,5-Trimethylpyridine/Omeprazole
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
73590-58-6
AC1L1IIJ
AC-401
AGI-010
AKOS005066653
Antra
Antra MUPS
Audazol
Aulcer
AULCER
Axagon
Belmazol
BIDD:GT0189
Bio-0888
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
C07324
CAS-73590-58-6
CCRIS 7099
Ceprandal
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID4594
CPD000058847
D00455
Danlox
DB00338
DB00736
Demeprazol
Desec
Dizprazol
DM-3458
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
esomeprazol
Esomeprazole
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168-68
H168/68
H-168/68
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
IDI1_032523
Indurgan
Inhibitron
Inhipump
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
LS-7629
Lucen
Maybridge4_002645
Mepral
Miol
Miracid
MLS000069373
MLS001076112
MLS001424148
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
Mopral
Morecon
NCGC00016925-01
|
NCGC00016925-02
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium IV
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
omeprazole
Omeprazole
Omeprazole (JAN/USP/INN)
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazole Pellets
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
OMP
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Prazentol
Prazidec
Prazolit
Prestwick_808
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prilosec
Prilosec (TN)
Prilosec OTC
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
SAM001246900
SAN-15
Sanamidol
Secrepina
SMR000058847
SPBio_002306
STK623746
Tedec Ulceral
TL8005099
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
UNII-KG60484QX9
UPCMLD-DP075
UPCMLD-DP075:001
Victrix
Zefxon
Zegerid
Zepral
Zimor
Zoltum
|
|
5 |
|
Antacids |
|
Phase 3 |
|
|
|
6 |
|
Anti-Ulcer Agents |
|
Phase 3 |
|
|
|
7 |
|
Proton pump inhibitors |
|
Phase 3 |
|
|
|
8 |
|
Pharmaceutical Solutions |
|
Phase 2, Phase 3 |
|
|
|
9 |
|
Pioglitazone |
Approved, Investigational |
Phase 2 |
|
111025-46-8 |
4829
|
Synonyms:
(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione
(+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
105355-27-9
111025-46-8
198077-89-3
2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione
5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione
5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
AB1004597
AC-1021
AC1L1J1Q
Actos
Actos (TN)
Actost
AD 4833
AD-4833
BRD-A48430263-003-02-4
BSPBio_002723
C07675
C19H20N2O3S
CHEBI:8228
CHEMBL595
CID4829
D08378
DB01132
Duetact
Glustin
HMS2089H14
HS-0047
HSDB 7322
|
I06-0089
KBio2_002103
KBio2_004671
KBio2_007239
KBio3_001943
KBioGR_001619
KBioSS_002103
LS-151327
MolPort-002-508-211
NCGC00163128-01
NCGC00163128-02
nchembio790-comp10
Pioglitazona
Pioglitazona [INN-Spanish]
Pioglitazone
pioglitazone (INN)
Pioglitazone [Ban:Inn]
Pioglitazone [BAN:INN]
Pioglitazone [INN:BAN]
pioglitazone HCl
Pioglitazone HCl
Pioglitazone Hydrochloride
Pioglitazonum
Pioglitazonum [INN-Latin]
SPBio_001897
Spectrum_001623
Spectrum2_001679
Spectrum3_001002
Spectrum4_001130
Spectrum5_001480
Spectrum5_002067
U 72107
U 72107A
U72,107A
U-72107
UNII-X4OV71U42S
Zactos
|
|
10 |
|
Hypoglycemic Agents |
|
Phase 2 |
|
|
|
11 |
|
insulin |
|
Phase 2 |
|
|
|
12 |
|
Insulin, Globin Zinc |
|
Phase 2 |
|
|
|
13 |
|
Menadione |
Approved, Nutraceutical |
Phase 1 |
|
58-27-5 |
4055
|
Synonyms:
03AAE1E9-B215-45AF-976C-91E61894A467
1,4-Naphthalenedione, 2-methyl-, radical ion(1-)
2-Methyl-1,4-naftochinon
2-Methyl-1,4-naftochinon [Czech]
2-Methyl-1,4-naphthalendione
2-Methyl-1,4-naphthalenedione
2-Methyl-1,4-Naphthalenedione
2-Methyl-1,4-naphthochinon
2-Methyl-1,4-naphthochinon [German]
2-Methyl-1,4-naphthodione
2-Methyl-1,4-naphthoquinone
2-methyl-1,4-naphthoquinone, 5
2-methylnaphthalene-1,4-dione
2-Methylnaphthoquinone
34524-96-4
3-Methyl-1,4-naphthoquinone
47775_SUPELCO
58-27-5
72060-21-0
AC1L1HBA
AC1Q2HB3
AI3-14700
AKOS004910447
Aquakay
Aquinone
ARONIS24154
BB_NC-2319
BIDD:ER0556
Bio1_000471
Bio1_000960
Bio1_001449
BPBio1_000592
BSPBio_000538
C05377
C11H8O2
CAS-58-27-5
CCRIS 6672
CHEBI:28869
CHEMBL590
CID4055
cMAP_000077
CPD-3766
D02335
DB00170
DivK1c_000080
DivK1c_006287
EINECS 200-372-6
Hemodal
HMS1569K20
HMS1921P06
HMS2092F12
HMS500D22
HSDB 3354
I14-2821
IDI1_000080
InChI=1/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H
Juva-K
Kaergona
Kanone
Kappaxan
Kappaxan (VAN)
Kappaxin
Kappaxin (TN)
Karcon
Kareon
Kativ-G
Kayklot
Kaykot
Kaynone
Kayquinone
KBio1_000080
KBio1_001231
KBio2_001708
KBio2_002527
KBio2_004276
KBio2_005095
KBio2_006844
KBio2_007663
KBio3_003005
KBioGR_000984
KBioGR_002527
KBioSS_001708
KBioSS_002535
|
Kipca
Kipca, oil soluble
Kipca-Oil Soluble
Klottone
Koaxin
Kolklot
K-Thrombyl
K-Vitan
LS-95653
LS-95654
M0373
M5625_SIGMA
M9429_SIGMA
Memodol
Menadion
menadione
Menadione
Menadione (K3)
Menadione (USP)
Menadione [USAN:BAN]
Menadione semiquinone
Menadionum
Menaphthene
Menaphthon
Menaphthone
Menaphtone
Menaquinone
Menaquinone 0
Menaquinone O
Methyl-1,4-naphthalenedione
Methyl-1,4-naphthoquinone
Methylnaphthoquinone
Mitenon
Mitenone
MLS000069420
MLS001148443
MNQ
MolPort-001-766-699
NCGC00016258-01
NCGC00094978-01
NCGC00094978-02
nchembio.109-comp5
NCI60_003945
NCIMech_000105
NINDS_000080
NSC 4170
NSC4170
Panosine
Prestwick_313
Prestwick0_000459
Prestwick1_000459
Prestwick2_000459
Prestwick3_000459
Prokayvit
QTL1_000056
S1949_Selleck
SMR000059102
SMR000653532
SPBio_001267
SPBio_002477
SpecPlus_000191
Spectrum_001228
SPECTRUM1502254
Spectrum2_001194
Spectrum4_000722
Spectrum5_001764
Synkay
Thyloquinone
UNII-723JX6CXY5
Usaf ek-5185
Vicasol
Vitamin K 3
Vitamin K0
Vitamin K2
Vitamin K2(0)
Vitamin K3
Vitamin K3 : 2-Methyl-1,4-naphthoquinone
Vitamin K3: 1,4-Dihydro-1,4-dioxo-2-methylnaphthalene
Vitamin-?K3
VK3
WLN: L66 BV EVJ C1
ZINC00001677
|
|
14 |
|
Phytonadione |
Approved, Investigational, Nutraceutical |
Phase 1 |
|
84-80-0 |
5284607
4812
|
Synonyms:
.alpha.-Phylloquinone
1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-)
10485-69-5
11104-38-4
15973-57-6
2-(3,7,11,15-Tetramethylhexadec-2-enyl)-3-methylnaphthalene-1,4-dione
2', 3'-trans-Vitamin K1
2',3'-trans-Vitamin K1
27696-10-2
2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalened- ione
2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione
2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione
2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone
2-Methyl-3-[(2e)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone
2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
2-Methyl-3-phythyl-1,4-naphthochinon
2-Methyl-3-phytyl-1,4-naphthochinon
2-Methyl-3-phytyl-1,4-naphthochinon [German]
2-Methyl-3-phytyl-1,4-naphthoquinone
2-METHYL-3-PHYTYL-14-NAPHTHOQUINONE
3-Phytylmenadione
50926-17-5
84-80-0
AC1NQX34
AC1Q6B3J
alpha-Phylloquinone
Antihemorrhagic vitamin
Aqua mephyton
Aqua-Mephytin
Aquamephyton
AR-1E3503
C02059
C31H46O2
CID5280483
Combinal K1
D00148
DB01022
EINECS 201-564-2
EINECS 234-330-3
EINECS 279-833-9
Fitomenadiona
Fitomenadiona [INN-Spanish]
Fitomenadione
Fitomenadione [DCIT]
HSDB 3162
Kativ N
Kephton
Kinadion
|
K-Ject
Konakion
LS-94617
LT00452032
Mephyton
Mephyton (TN)
MLS001332659
MLS001332660
MolPort-001-785-978
Monodion
Mono-Kay
NCGC00159423-02
NSC 270681
NSC270681
P0642
Phyllochinon
Phyllochinon [German]
Phyllochinonum
phyllohydroquinone
Phylloquinone
Phylloquinone (8CI)
Phythyl-menadion
Phythyl-menadion (GERMAN)
Phytomenadione
Phytomenadione (INN)
Phytomenadionum
Phytomenadionum [INN-Latin]
phytonadione
Phytonadione (JP15/USP)
Phytonadione [USAN:JAN]
Phytonadionum
Phytylmenadione
SMR000059144
ST075162
Synthex P
trans-Phylloquinone
UNII-A034SE7857
Vitamin k
Vitamin K
VITAMIN K
Vitamin K 1
Vitamin K1
VITAMIN K1
Vitamin K1 (generic)
Vitamin K1 (TN)
Vitamin K1 (VAN)
Vitamin K1(20)
α-phylloquinone
|
|
15 |
|
Antifibrinolytic Agents |
|
Phase 1 |
|
|
|
16 |
|
Coagulants |
|
Phase 1 |
|
|
|
17 |
|
Hemostatics |
|
Phase 1 |
|
|
|
18 |
|
Micronutrients |
|
Phase 1 |
|
|
|
19 |
|
Trace Elements |
|
Phase 1 |
|
|
|
20 |
|
Vitamins |
|
Phase 1 |
|
|
|
21 |
|
Menaquinone |
Nutraceutical |
Phase 1 |
|
|
|
22 |
|
naphthoquinone |
Nutraceutical |
Phase 1 |
|
|
|
23 |
|
Vitamin K |
Nutraceutical |
Phase 1 |
|
|
|
24 |
|
Nicotine |
Approved |
|
|
54-11-5 |
89594
942
|
Synonyms:
(−
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(−)-nicotine
(-)-Nicotine
(-)-Nicotine solution
(+)-Nicotine
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(−)-nicotine
(S)-(-)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-methylpyrollidino)pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
3-N-Methylpyrrolidine
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
a -N-Methylpyrrolidine
AC1L3I79
AC1Q3ZOC
AI3-03424
alpha-N-Methylpyrrolidine
a-N-Methylpyrrolidine
BB_NC-0777
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
BIDD:GT0599
Black Leaf
Black Leaf 40
bmse000105
BRD-K05395900-322-02-1
C00745
Campbell's Nico-Soap
Caswell No. 597
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
Commit
CPD000059074
D03365
delta-Nicotine
Destruxol
Destruxol Orchid Spray
DL-tetrahydronicotyrine
D-Nicotine
EINECS 200-193-3
Emo-Nik
ENT 3,424
EPA Pesticide Chemical Code 056702
Flux Maag
Fumeto bac
Fumetobac
Habitrol
|
Habitrol (TN)
HSDB 1107
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
L-Nicotine
LS-202
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MLS001055457
MLS001335905
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
Niagara P.A. Dust
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nico-Dust
Nico-Fume
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
nicotine
Nicotine
Nicotine (compounds related to)
Nicotine (USP)
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotine Alkaloid
NICOTINE AND SALTS
Nicotine betadex
Nicotine Patch
Nicotine polacrilex
Nicotine Polacrilex
nicotine replacement patch
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nic-Sal
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
NSC 5065
NSC97238
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
|
|
25 |
|
Teriparatide |
Approved, Investigational |
|
|
52232-67-4 |
16133850
|
Synonyms:
52232-67-4
D06078
Forteo
Forteo (TN)
TERIPARATIDE
|
Teriparatide (genetical recombination)
Teriparatide (genetical recombination) (JAN)
Teriparatide (USAN/INN)
Teriparatide recombinant human
|
|
26 |
|
Vitamin D |
Approved, Nutraceutical, Vet_approved |
|
|
1406-16-2 |
|
Synonyms:
|
Vitamin D, unspecified form
|
|
27 |
|
Bile Acids and Salts |
|
|
|
|
|
28 |
|
Antibodies |
|
|
|
|
|
29 |
|
Immunoglobulins |
|
|
|
|
|
30 |
|
Cholic Acids |
|
|
|
|
|
31 |
|
Bone Density Conservation Agents |
|
|
|
|
|
32 |
|
Calcium, Dietary |
|
|
|
|
|
33 |
|
glucocorticoids |
|
|
|
|
|
Interventional clinical trials:
(show all 29)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency |
Completed |
NCT01327703
|
Phase 4 |
Panzytrat® 25,000;Kreon® 25,000 |
2 |
Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea |
Completed |
NCT00572975
|
Phase 4 |
|
3 |
Enzyme Suppletion in Exocrine Pancreatic Dysfunction |
Completed |
NCT01430234
|
Phase 4 |
Panzytrat 25.000 FIP-E units of Lipase |
4 |
Pancreatic Enzyme Suppletion in Pancreatic Cancer |
Withdrawn |
NCT01401387
|
Phase 4 |
|
5 |
Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea |
Completed |
NCT00559364
|
Phase 3 |
Viokase® 16;Placebo;Proton pump inhibitor (PPI);Omeprazole |
6 |
Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF) |
Completed |
NCT00880100
|
Phase 3 |
Ultrase® MT12 |
7 |
Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis |
Completed |
NCT00432861
|
Phase 3 |
PANCRECARB® (pancrelipase);Placebo |
8 |
Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI) |
Completed |
NCT00408317
|
Phase 3 |
Ultrase® MT20;Placebo |
9 |
A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency |
Completed |
NCT00662675
|
Phase 3 |
Pancrease MT 10.5, or MT 21;Placebo for Pancrease MT 10.5 or MT 21 |
10 |
Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) |
Completed |
NCT00513682
|
Phase 3 |
Ultrase® MT20 |
11 |
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation |
Active, not recruiting |
NCT01967888
|
Phase 2, Phase 3 |
Reparixin;Placebo |
12 |
Creon in HIV Patients With Steatorrhea |
Terminated |
NCT00623025
|
Phase 3 |
Creon 25000;Placebo |
13 |
Effectiveness of Pancreatic Enzymes in Patients Pancreatic Insufficient: Comparison of Two Drugs |
Withdrawn |
NCT01228643
|
Phase 3 |
|
14 |
An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption |
Completed |
NCT00217204
|
Phase 2 |
Pancrelipase microtablets |
15 |
Tolerance and Digestibility of a New Formula in Healthy Infants |
Completed |
NCT01184378
|
Phase 2 |
|
16 |
An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI) |
Completed |
NCT00559052
|
Phase 2 |
VIOKASE 16 |
17 |
Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality |
Completed |
NCT00782795
|
Phase 2 |
Pioglitazone;Placebo |
18 |
A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI) |
Completed |
NCT00676702
|
Phase 1 |
Pancrelipase in combination with Ensure Plus |
19 |
Comparison of Feasibility Between Internal and External Pancreatic Drainage in Pancreaticoduodenectomy |
Unknown status |
NCT01023594
|
|
|
20 |
Randomized Study of Pancrelipase With Bicarbonate (PANCRECARB) Capsules in Reducing Steatorrhea in Patients With Cystic Fibrosis |
Completed |
NCT00006063
|
|
pancrelipase with bicarbonate |
21 |
Effect of Potato Fiber on Appetite and Fecal Fat Excretion |
Completed |
NCT02957318
|
|
|
22 |
Incidence and Risk Factor of Post-ERCP Pancreatitis in Chronic Pancreatitis |
Completed |
NCT02781987
|
|
|
23 |
Horton & Maizy Pilot Study for Resistant to Starch |
Completed |
NCT01338571
|
|
|
24 |
Timing of Surgical Intervention After Percutaneous Catheter Drainage in STEP UP Approach for Severe Acute Pancreatitis |
Completed |
NCT01527084
|
|
|
25 |
The FOCCUS Study: "Focusing on Cancers Chemotherapys' Untreated Symptoms" |
Completed |
NCT02121626
|
|
|
26 |
Celiac Disease Diagnosis in Patients With Weakly Positive Serum Anti-Transglutaminase: Duodenal Anti-Endomysium Assay. |
Recruiting |
NCT02242123
|
|
|
27 |
The REPLACE Registry |
Recruiting |
NCT03115086
|
|
|
28 |
Study of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders |
Recruiting |
NCT02252679
|
|
|
29 |
The Natural History of Chronic Pancreatitis |
Active, not recruiting |
NCT03324698
|
|
|
Cochrane evidence based reviews: steatorrhea
|